Imigran Radis

Sumatriptan, the active ingredient in Imigran Radis, is a serotonin (5‑HT1) receptor agonist presented as a tablet for oral use. It provides acute treatment of migraine attacks in adults.

GNH USA supplies Imigran Radis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran Radis (sumatriptan) belongs to the serotonin receptor agonist class used for migraine management. - Migraine (acute treatment): Relieves headache pain and associated symptoms when taken at the onset of an attack.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient light‑headedness. - Tingling sensations: paresthesia in extremities. - Chest discomfort: pressure or tightness in the chest.

Serious or Rare Side Effects: - Coronary vasospasm: chest pain due to reduced coronary blood flow. - Severe hypertension: sudden increase in blood pressure. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents. - Allergic reaction: rash, swelling, or difficulty breathing.

Before using Imigran Radis, consider the following precautions: - Cardiovascular disease: avoid if you have ischemic heart disease, uncontrolled hypertension, or cerebrovascular disorders. - Hemiplegic or basilar migraine: contraindicated due to increased vascular risk. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Liver or renal impairment: dose adjustment may be required under medical supervision. - Pregnancy and lactation: discuss potential risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imigran Radis may interact with other medicines as follows: Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergot derivatives: additive vasoconstrictive effects. - SSRIs, SNRIs, or other triptans: increased chance of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood pressure‑lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma levels. - Other serotonergic agents (e.g., tramadol): monitor for serotonergic toxicity.